The groundbreaking phase III double-blind RELAY trial demonstrated that adding ramucirumab to erlotinib improved PFS (19.4 vs.12.4 months) in treatment-naïve EGFR-mutated metastatic NSCLC [21]. Here, EGFR is linked to non-small cell lung carcinoma.